Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis
Purpose Therapeutic exploitation of angiogenesis in breast cancer has been limited by the lack of reliable biomarkers. Circulating small-sized endothelial microparticles (sEMP) are likely to play a significant role as messengers of angiogenesis. Higher levels of EMP have been observed in cancer pati...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2018-05, Vol.169 (1), p.83-92 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 92 |
|---|---|
| container_issue | 1 |
| container_start_page | 83 |
| container_title | Breast cancer research and treatment |
| container_volume | 169 |
| creator | García Garre, Elisa Luengo Gil, Ginés Montoro García, Silvia Gonzalez Billalabeitia, Enrique Zafra Poves, Marta García Martinez, Elena Roldán Schilling, Vanessa Navarro Manzano, Esther Ivars Rubio, Alejandra Lip, Gregory Y. H. Ayala de la Peña, Francisco |
| description | Purpose
Therapeutic exploitation of angiogenesis in breast cancer has been limited by the lack of reliable biomarkers. Circulating small-sized endothelial microparticles (sEMP) are likely to play a significant role as messengers of angiogenesis. Higher levels of EMP have been observed in cancer patients, but their prognostic value in breast cancer is unknown. Our aim was to determine the value of circulating sEMP as a marker of response to chemotherapy in breast cancer.
Methods
We included patients with breast cancer treated with neoadjuvant or first-line chemotherapy. Baseline and post-treatment circulating sEMP (CD144+) were quantified using a flow cytometer approach specifically designed for analysis of small-sized particles (0.1–0.5 μm). Small-sized EMP response was defined as a post-treatment decrease of sEMP larger than the median decrease of sEMP after chemotherapy. Baseline and post-chemotherapy VEGFA levels were determined with ELISA.
Results
Forty-four breast cancer patients were included (19 with metastatic and 25 with locally advanced disease). Median levels of sEMP decreased after chemotherapy (
P
= 0.005). Response to chemotherapy showed a non-significant trend to associate with sEMP response (
P
= 0.056). A sEMP response was observed in 51% of patients and was associated with better overall survival (HR 0.18; 95% CI 0.04–0.87;
P
= 0.02) and progression free survival (HR 0.30; 95% CI 0.09–0.99;
P
= 0.04) in the group of women with metastatic disease. Post-chemotherapy decrease of VEGFA levels was not associated with breast cancer prognosis.
Conclusions
Our results did not support sEMP as a marker of response to chemotherapy. However, our exploratory analysis suggests that in patients with metastatic breast cancer, the decrease of sEMP levels after chemotherapy is associated with better overall and disease free survival and might be superior to VEGFA levels as an angiogenesis-related prognostic marker. |
| doi_str_mv | 10.1007/s10549-017-4656-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989612379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A536481648</galeid><sourcerecordid>A536481648</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-52205aed7f5c03fd46e8e48823edf7aae9c908ff89b40a91d942785a6b15dfed3</originalsourceid><addsrcrecordid>eNp1ktFqFDEUhgdR7Fp9AG8kIIg3U5OZyWTiXVlaFQre6HU4m5zspmQmY5IBdx_DJzbLVm1FCSEk-f6fc5K_ql4yesEoFe8So7yTNWWi7nre14dH1Ypx0daiYeJxtaKsF3U_0P6sepbSLaVUCiqfVmeNbDs6DM2q-rF2US8espu2JI3gfZ3cAQ3ByYS8Q-_Ak9HpGGaI2WmPiUAic0TjdA4xkWCJ9m5yuoBhyTqMSMBmjETvcDx6RJj3xIZINhEhZaJh0hjfE5gIfp99iFCM9mULfp9cel49seATvrhbz6uv11df1h_rm88fPq0vb2rN2z7XvGkoBzTCck1ba7oeB-xKUy0aKwBQakkHawe56ShIZmTXiIFDv2HcWDTtefX25DvH8G3BlNXokkbvYcKwJMXkIHvWtEIW9PVf6G1YYqn3SMlGCt5y_ofagkflJhtyBH00VZel5G5gZRbq4h9UGQbLO4cJrSvnDwRv7gl2CD7vUvBLdmFKD0F2AstvpRTRqjm6EeJeMaqOgVGnwKgSGHUMjDoUzau7zpbNiOa34ldCCtCcgFSupi3Ge63_1_Un8yvNog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1992975355</pqid></control><display><type>article</type><title>Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>García Garre, Elisa ; Luengo Gil, Ginés ; Montoro García, Silvia ; Gonzalez Billalabeitia, Enrique ; Zafra Poves, Marta ; García Martinez, Elena ; Roldán Schilling, Vanessa ; Navarro Manzano, Esther ; Ivars Rubio, Alejandra ; Lip, Gregory Y. H. ; Ayala de la Peña, Francisco</creator><creatorcontrib>García Garre, Elisa ; Luengo Gil, Ginés ; Montoro García, Silvia ; Gonzalez Billalabeitia, Enrique ; Zafra Poves, Marta ; García Martinez, Elena ; Roldán Schilling, Vanessa ; Navarro Manzano, Esther ; Ivars Rubio, Alejandra ; Lip, Gregory Y. H. ; Ayala de la Peña, Francisco</creatorcontrib><description>Purpose
Therapeutic exploitation of angiogenesis in breast cancer has been limited by the lack of reliable biomarkers. Circulating small-sized endothelial microparticles (sEMP) are likely to play a significant role as messengers of angiogenesis. Higher levels of EMP have been observed in cancer patients, but their prognostic value in breast cancer is unknown. Our aim was to determine the value of circulating sEMP as a marker of response to chemotherapy in breast cancer.
Methods
We included patients with breast cancer treated with neoadjuvant or first-line chemotherapy. Baseline and post-treatment circulating sEMP (CD144+) were quantified using a flow cytometer approach specifically designed for analysis of small-sized particles (0.1–0.5 μm). Small-sized EMP response was defined as a post-treatment decrease of sEMP larger than the median decrease of sEMP after chemotherapy. Baseline and post-chemotherapy VEGFA levels were determined with ELISA.
Results
Forty-four breast cancer patients were included (19 with metastatic and 25 with locally advanced disease). Median levels of sEMP decreased after chemotherapy (
P
= 0.005). Response to chemotherapy showed a non-significant trend to associate with sEMP response (
P
= 0.056). A sEMP response was observed in 51% of patients and was associated with better overall survival (HR 0.18; 95% CI 0.04–0.87;
P
= 0.02) and progression free survival (HR 0.30; 95% CI 0.09–0.99;
P
= 0.04) in the group of women with metastatic disease. Post-chemotherapy decrease of VEGFA levels was not associated with breast cancer prognosis.
Conclusions
Our results did not support sEMP as a marker of response to chemotherapy. However, our exploratory analysis suggests that in patients with metastatic breast cancer, the decrease of sEMP levels after chemotherapy is associated with better overall and disease free survival and might be superior to VEGFA levels as an angiogenesis-related prognostic marker.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-017-4656-z</identifier><identifier>PMID: 29340882</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adjuvant chemotherapy ; Adult ; Aged ; Angiogenesis ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Cancer metastasis ; Cancer patients ; Cancer research ; Care and treatment ; Cell-Derived Microparticles - genetics ; Cell-Derived Microparticles - pathology ; Chemotherapy ; Clinical outcomes ; Clinical Trial ; Development and progression ; Disease-Free Survival ; Endothelium ; Endothelium - pathology ; Enzyme-linked immunosorbent assay ; Female ; Humans ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Microparticles ; Middle Aged ; Neoadjuvant Therapy ; Oncology ; Patient outcomes ; Prognosis ; Survival ; Treatment Outcome ; Vascular endothelial growth factor</subject><ispartof>Breast cancer research and treatment, 2018-05, Vol.169 (1), p.83-92</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>COPYRIGHT 2018 Springer</rights><rights>Breast Cancer Research and Treatment is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-52205aed7f5c03fd46e8e48823edf7aae9c908ff89b40a91d942785a6b15dfed3</citedby><cites>FETCH-LOGICAL-c536t-52205aed7f5c03fd46e8e48823edf7aae9c908ff89b40a91d942785a6b15dfed3</cites><orcidid>0000-0001-6311-920X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-017-4656-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-017-4656-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29340882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García Garre, Elisa</creatorcontrib><creatorcontrib>Luengo Gil, Ginés</creatorcontrib><creatorcontrib>Montoro García, Silvia</creatorcontrib><creatorcontrib>Gonzalez Billalabeitia, Enrique</creatorcontrib><creatorcontrib>Zafra Poves, Marta</creatorcontrib><creatorcontrib>García Martinez, Elena</creatorcontrib><creatorcontrib>Roldán Schilling, Vanessa</creatorcontrib><creatorcontrib>Navarro Manzano, Esther</creatorcontrib><creatorcontrib>Ivars Rubio, Alejandra</creatorcontrib><creatorcontrib>Lip, Gregory Y. H.</creatorcontrib><creatorcontrib>Ayala de la Peña, Francisco</creatorcontrib><title>Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
Therapeutic exploitation of angiogenesis in breast cancer has been limited by the lack of reliable biomarkers. Circulating small-sized endothelial microparticles (sEMP) are likely to play a significant role as messengers of angiogenesis. Higher levels of EMP have been observed in cancer patients, but their prognostic value in breast cancer is unknown. Our aim was to determine the value of circulating sEMP as a marker of response to chemotherapy in breast cancer.
Methods
We included patients with breast cancer treated with neoadjuvant or first-line chemotherapy. Baseline and post-treatment circulating sEMP (CD144+) were quantified using a flow cytometer approach specifically designed for analysis of small-sized particles (0.1–0.5 μm). Small-sized EMP response was defined as a post-treatment decrease of sEMP larger than the median decrease of sEMP after chemotherapy. Baseline and post-chemotherapy VEGFA levels were determined with ELISA.
Results
Forty-four breast cancer patients were included (19 with metastatic and 25 with locally advanced disease). Median levels of sEMP decreased after chemotherapy (
P
= 0.005). Response to chemotherapy showed a non-significant trend to associate with sEMP response (
P
= 0.056). A sEMP response was observed in 51% of patients and was associated with better overall survival (HR 0.18; 95% CI 0.04–0.87;
P
= 0.02) and progression free survival (HR 0.30; 95% CI 0.09–0.99;
P
= 0.04) in the group of women with metastatic disease. Post-chemotherapy decrease of VEGFA levels was not associated with breast cancer prognosis.
Conclusions
Our results did not support sEMP as a marker of response to chemotherapy. However, our exploratory analysis suggests that in patients with metastatic breast cancer, the decrease of sEMP levels after chemotherapy is associated with better overall and disease free survival and might be superior to VEGFA levels as an angiogenesis-related prognostic marker.</description><subject>Adjuvant chemotherapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Angiogenesis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer metastasis</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Care and treatment</subject><subject>Cell-Derived Microparticles - genetics</subject><subject>Cell-Derived Microparticles - pathology</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Clinical Trial</subject><subject>Development and progression</subject><subject>Disease-Free Survival</subject><subject>Endothelium</subject><subject>Endothelium - pathology</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Female</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Microparticles</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Prognosis</subject><subject>Survival</subject><subject>Treatment Outcome</subject><subject>Vascular endothelial growth factor</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1ktFqFDEUhgdR7Fp9AG8kIIg3U5OZyWTiXVlaFQre6HU4m5zspmQmY5IBdx_DJzbLVm1FCSEk-f6fc5K_ql4yesEoFe8So7yTNWWi7nre14dH1Ypx0daiYeJxtaKsF3U_0P6sepbSLaVUCiqfVmeNbDs6DM2q-rF2US8espu2JI3gfZ3cAQ3ByYS8Q-_Ak9HpGGaI2WmPiUAic0TjdA4xkWCJ9m5yuoBhyTqMSMBmjETvcDx6RJj3xIZINhEhZaJh0hjfE5gIfp99iFCM9mULfp9cel49seATvrhbz6uv11df1h_rm88fPq0vb2rN2z7XvGkoBzTCck1ba7oeB-xKUy0aKwBQakkHawe56ShIZmTXiIFDv2HcWDTtefX25DvH8G3BlNXokkbvYcKwJMXkIHvWtEIW9PVf6G1YYqn3SMlGCt5y_ofagkflJhtyBH00VZel5G5gZRbq4h9UGQbLO4cJrSvnDwRv7gl2CD7vUvBLdmFKD0F2AstvpRTRqjm6EeJeMaqOgVGnwKgSGHUMjDoUzau7zpbNiOa34ldCCtCcgFSupi3Ge63_1_Un8yvNog</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>García Garre, Elisa</creator><creator>Luengo Gil, Ginés</creator><creator>Montoro García, Silvia</creator><creator>Gonzalez Billalabeitia, Enrique</creator><creator>Zafra Poves, Marta</creator><creator>García Martinez, Elena</creator><creator>Roldán Schilling, Vanessa</creator><creator>Navarro Manzano, Esther</creator><creator>Ivars Rubio, Alejandra</creator><creator>Lip, Gregory Y. H.</creator><creator>Ayala de la Peña, Francisco</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6311-920X</orcidid></search><sort><creationdate>20180501</creationdate><title>Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis</title><author>García Garre, Elisa ; Luengo Gil, Ginés ; Montoro García, Silvia ; Gonzalez Billalabeitia, Enrique ; Zafra Poves, Marta ; García Martinez, Elena ; Roldán Schilling, Vanessa ; Navarro Manzano, Esther ; Ivars Rubio, Alejandra ; Lip, Gregory Y. H. ; Ayala de la Peña, Francisco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-52205aed7f5c03fd46e8e48823edf7aae9c908ff89b40a91d942785a6b15dfed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adjuvant chemotherapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Angiogenesis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer metastasis</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Care and treatment</topic><topic>Cell-Derived Microparticles - genetics</topic><topic>Cell-Derived Microparticles - pathology</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Clinical Trial</topic><topic>Development and progression</topic><topic>Disease-Free Survival</topic><topic>Endothelium</topic><topic>Endothelium - pathology</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Female</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Microparticles</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Prognosis</topic><topic>Survival</topic><topic>Treatment Outcome</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García Garre, Elisa</creatorcontrib><creatorcontrib>Luengo Gil, Ginés</creatorcontrib><creatorcontrib>Montoro García, Silvia</creatorcontrib><creatorcontrib>Gonzalez Billalabeitia, Enrique</creatorcontrib><creatorcontrib>Zafra Poves, Marta</creatorcontrib><creatorcontrib>García Martinez, Elena</creatorcontrib><creatorcontrib>Roldán Schilling, Vanessa</creatorcontrib><creatorcontrib>Navarro Manzano, Esther</creatorcontrib><creatorcontrib>Ivars Rubio, Alejandra</creatorcontrib><creatorcontrib>Lip, Gregory Y. H.</creatorcontrib><creatorcontrib>Ayala de la Peña, Francisco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García Garre, Elisa</au><au>Luengo Gil, Ginés</au><au>Montoro García, Silvia</au><au>Gonzalez Billalabeitia, Enrique</au><au>Zafra Poves, Marta</au><au>García Martinez, Elena</au><au>Roldán Schilling, Vanessa</au><au>Navarro Manzano, Esther</au><au>Ivars Rubio, Alejandra</au><au>Lip, Gregory Y. H.</au><au>Ayala de la Peña, Francisco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>169</volume><issue>1</issue><spage>83</spage><epage>92</epage><pages>83-92</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
Therapeutic exploitation of angiogenesis in breast cancer has been limited by the lack of reliable biomarkers. Circulating small-sized endothelial microparticles (sEMP) are likely to play a significant role as messengers of angiogenesis. Higher levels of EMP have been observed in cancer patients, but their prognostic value in breast cancer is unknown. Our aim was to determine the value of circulating sEMP as a marker of response to chemotherapy in breast cancer.
Methods
We included patients with breast cancer treated with neoadjuvant or first-line chemotherapy. Baseline and post-treatment circulating sEMP (CD144+) were quantified using a flow cytometer approach specifically designed for analysis of small-sized particles (0.1–0.5 μm). Small-sized EMP response was defined as a post-treatment decrease of sEMP larger than the median decrease of sEMP after chemotherapy. Baseline and post-chemotherapy VEGFA levels were determined with ELISA.
Results
Forty-four breast cancer patients were included (19 with metastatic and 25 with locally advanced disease). Median levels of sEMP decreased after chemotherapy (
P
= 0.005). Response to chemotherapy showed a non-significant trend to associate with sEMP response (
P
= 0.056). A sEMP response was observed in 51% of patients and was associated with better overall survival (HR 0.18; 95% CI 0.04–0.87;
P
= 0.02) and progression free survival (HR 0.30; 95% CI 0.09–0.99;
P
= 0.04) in the group of women with metastatic disease. Post-chemotherapy decrease of VEGFA levels was not associated with breast cancer prognosis.
Conclusions
Our results did not support sEMP as a marker of response to chemotherapy. However, our exploratory analysis suggests that in patients with metastatic breast cancer, the decrease of sEMP levels after chemotherapy is associated with better overall and disease free survival and might be superior to VEGFA levels as an angiogenesis-related prognostic marker.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29340882</pmid><doi>10.1007/s10549-017-4656-z</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6311-920X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2018-05, Vol.169 (1), p.83-92 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1989612379 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adjuvant chemotherapy Adult Aged Angiogenesis Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Breast cancer Breast Neoplasms - blood Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer metastasis Cancer patients Cancer research Care and treatment Cell-Derived Microparticles - genetics Cell-Derived Microparticles - pathology Chemotherapy Clinical outcomes Clinical Trial Development and progression Disease-Free Survival Endothelium Endothelium - pathology Enzyme-linked immunosorbent assay Female Humans Medical prognosis Medicine Medicine & Public Health Metastases Metastasis Microparticles Middle Aged Neoadjuvant Therapy Oncology Patient outcomes Prognosis Survival Treatment Outcome Vascular endothelial growth factor |
| title | Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T20%3A42%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20small-sized%20endothelial%20microparticles%20as%20predictors%20of%20clinical%20outcome%20after%20chemotherapy%20for%20breast%20cancer:%20an%20exploratory%20analysis&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Garc%C3%ADa%20Garre,%20Elisa&rft.date=2018-05-01&rft.volume=169&rft.issue=1&rft.spage=83&rft.epage=92&rft.pages=83-92&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-017-4656-z&rft_dat=%3Cgale_proqu%3EA536481648%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1992975355&rft_id=info:pmid/29340882&rft_galeid=A536481648&rfr_iscdi=true |